Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry.

IF 3.1 2区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Eric Thomas Roberts, Nick Bansback, Chien-Wen Tseng, Stephen Shiboski, Jing Li, Gabriela Schmajuk, Jinoos Yazdany
{"title":"Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry.","authors":"Eric Thomas Roberts, Nick Bansback, Chien-Wen Tseng, Stephen Shiboski, Jing Li, Gabriela Schmajuk, Jinoos Yazdany","doi":"10.1111/1475-6773.14410","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the variability in new infliximab biosimilar starts as well as switching from bio-originator to biosimilar infliximab, across insurance payers and rheumatology practices nationally.</p><p><strong>Study setting and design: </strong>Data came from Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from over 1100 US rheumatologists. Key outcomes include ever use of a biosimilar, date of initiation, and date of switching. Key variables of interest include insurance payer and practice.</p><p><strong>Data sources and analytic sample: </strong>Secondary analysis of 37,560 patients aged ≥18 years administered infliximab (bio-originator or biosimilar) between April 2016 and September 2022 in Rheumatology Informatics System for Effectiveness. We tested for differences in use of biosimilar infliximab by demographic characteristics, socioeconomic status, and diagnosis using standard mean differences and multivariable modified Poisson regression. We used generalized estimating equations to assess the adjusted effect of insurance and year of initiation on new biosimilar starts. We analyzed variation in biosimilar switching by insurance, date of switch, and practice.</p><p><strong>Principal findings: </strong>A total of 8196 (21.8%) infliximab users ever used a biosimilar and use did not differ significantly by demographic or clinical characteristics. In 2022, uptake among new users was higher among those with Medicaid (55%; 95%CI 43%-68%) and private insurance (51%; 95%CI 46%-57%) compared to Medicare (36%; 95%CI 29%-43%). Few prevalent bio-originator infliximab users switched to a biosimilar, and switching was lowest among Medicare beneficiaries (7% vs. 14.2% in Medicaid and 16.9% among privately insured). In adjusted analyses, practice level differences explained 37% of variation among new biosimilar starts and 34% of variation among those switching to a biosimilar.</p><p><strong>Conclusions: </strong>Our findings underscore two critical areas for enhancing biosimilar infliximab usage: increasing switching among prevalent users and increasing uptake among Medicare beneficiaries initiating treatment. Significant variation in uptake across practices also suggests that local switching policies are likely key drivers of uptake.</p>","PeriodicalId":55065,"journal":{"name":"Health Services Research","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Services Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1475-6773.14410","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To analyze the variability in new infliximab biosimilar starts as well as switching from bio-originator to biosimilar infliximab, across insurance payers and rheumatology practices nationally.

Study setting and design: Data came from Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from over 1100 US rheumatologists. Key outcomes include ever use of a biosimilar, date of initiation, and date of switching. Key variables of interest include insurance payer and practice.

Data sources and analytic sample: Secondary analysis of 37,560 patients aged ≥18 years administered infliximab (bio-originator or biosimilar) between April 2016 and September 2022 in Rheumatology Informatics System for Effectiveness. We tested for differences in use of biosimilar infliximab by demographic characteristics, socioeconomic status, and diagnosis using standard mean differences and multivariable modified Poisson regression. We used generalized estimating equations to assess the adjusted effect of insurance and year of initiation on new biosimilar starts. We analyzed variation in biosimilar switching by insurance, date of switch, and practice.

Principal findings: A total of 8196 (21.8%) infliximab users ever used a biosimilar and use did not differ significantly by demographic or clinical characteristics. In 2022, uptake among new users was higher among those with Medicaid (55%; 95%CI 43%-68%) and private insurance (51%; 95%CI 46%-57%) compared to Medicare (36%; 95%CI 29%-43%). Few prevalent bio-originator infliximab users switched to a biosimilar, and switching was lowest among Medicare beneficiaries (7% vs. 14.2% in Medicaid and 16.9% among privately insured). In adjusted analyses, practice level differences explained 37% of variation among new biosimilar starts and 34% of variation among those switching to a biosimilar.

Conclusions: Our findings underscore two critical areas for enhancing biosimilar infliximab usage: increasing switching among prevalent users and increasing uptake among Medicare beneficiaries initiating treatment. Significant variation in uptake across practices also suggests that local switching policies are likely key drivers of uptake.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Health Services Research
Health Services Research 医学-卫生保健
CiteScore
4.80
自引率
5.90%
发文量
193
审稿时长
4-8 weeks
期刊介绍: Health Services Research (HSR) is a peer-reviewed scholarly journal that provides researchers and public and private policymakers with the latest research findings, methods, and concepts related to the financing, organization, delivery, evaluation, and outcomes of health services. Rated as one of the top journals in the fields of health policy and services and health care administration, HSR publishes outstanding articles reporting the findings of original investigations that expand knowledge and understanding of the wide-ranging field of health care and that will help to improve the health of individuals and communities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信